Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

The ACT-Accelerator is asking donor countries to contribute US$ 16.8 B of the $23.4 B total budget in immediate grant funding for Oct 2021 to Sept 2022 – with all funding figures rounded to the closest decimal. With $814 M of this $16.8 B already pledged, $16 B is now needed to close the immediate financing gap.

Closing this immediate $16 B financing gap would cover the most urgent work of the ACT-Accelerator’s constituent agencies, as set out in the initiative’s Strategic Plan and Budget, published in October 2021. It would cover procurement, research and development, product assessment, and rolling out vaccines, tests, and treatments, meeting the needs of low-income countries and the most vulnerable LMICs.

The aim is for the remaining $6.5 B of the $23.4 B budget to be self-financed by middle-income countries, using domestic resources to cover certain procurement needs,supported by multilateral development banks.

Separate to the ACT-Accelerator budget of US$ 23.4 billion, US$ 6.8 billion is needed for in-country delivery needs of vaccines and diagnostics, from a combination of domestic resources, multilateral development bank support, and further international grant financing support.

Closing the US$ 16 billion gap facing the ACT-Accelerator will enable the partnership to:
* in-country rollouts to get vaccines into arms, create a Pandemic Vaccine Pool of 600 million doses, support community engagement and cover ancillary costs for donations – contributing to countries’ national vaccination objectives towards the global target of 70% coverage in all countries by mid-2022
* Support clinical trials for treatments and vaccines, to help address variants of concern and initiate the development of broadly protective coronavirus vaccines.
https://www.who.int/news/item/09-02-2022-act-accelerator-calls-for-fair-share-based-financing-of-usdollar-23-billion-to-end-pandemic-as-global-emergency-in-2022